November 15, 1994CancerOpen Access

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

View Full Paper

Ask AI

Bookmark

Why the study?

Does high dose bolus therapy with interleukin-2 and alpha-interferon cause severe cardiac toxicity in patients with metastatic melanoma?

Population

16 patients with metastatic melanoma

Design

Case_series

Follow-up

up to 6 months

Authors

WKWim H.J. KruitErasmus MC Cancer Institute KPK. PuntUtrecht University SGS.H. GoeyElisabeth-TweeSteden Ziekenhuis

Discussion

Member takes

Implication

High-dose IL-2 plus alpha-interferon was associated with myocardial injury in metastatic melanoma; leaves open cardiac safety in larger prospective studies.

Structured PICO

Does high dose bolus therapy with interleukin-2 and alpha-interferon cause severe cardiac toxicity in patients with metastatic melanoma?

Population

16 patients with metastatic melanoma

Intervention

Interleukin-2 (IL-2) 12 MIU/m2 and alpha-interferon (alpha-IFN) 3 MIU/m2, given as intravenous bolus injections every 8 hours on Days 1-5, every 3 weeks for a total of three cycles

Outcome

Incidence of severe cardiac adverse effects (myocardial injury)safety

High-dose bolus therapy with IL-2 and alpha-interferon in metastatic melanoma is associated with an unacceptably high rate (44%) of severe, life-threatening cardiotoxicity.

Cite This Study

Kruit et al. (1994) studied this question.

synapsesocial.com/papers/6a710e63a528af2d65c3e258 https://doi.org/10.1002/1097-0142(19941115)74:10<2850::aid-cncr2820741018>3.0.co;2-t

View Full Paper

Ask AI

Bookmark

Implication

High-dose IL-2 plus alpha-interferon was associated with myocardial injury in metastatic melanoma; leaves open cardiac safety in larger prospective studies.

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider